TMCnet News

BioPharm Insight Releases CRO Report on Clinical Trial Activity in 3rd Quarter
[October 25, 2016]

BioPharm Insight Releases CRO Report on Clinical Trial Activity in 3rd Quarter


BioPharm Insight (BPI), the most comprehensive life science market intelligence and analytics solution, today released its exclusive Contract Research Organization (CRO) Report on competitive intelligence for the third quarter of 2016.

The report offers in-depth analysis of BioPharm Insight data from the CRO industry broken down by geography, therapeutic areas, and phases of development. It also highlights CRO opportunities, relationships and trends in the life sciences market.

Get the Full Report: www.biopharminsight.com/cro-activity-and-intelligence-report-3q16

The most active CROs, initiating the highest number of studies, for the third quarter identified in the report were PRA Health Sciences (NASDAQ: PRAH) and INC Research (NASDAQ: INCR), with eight studies each. Covance (NYSE: CVD) was next with seven studies, followed by Parexel (NASDAQ: PRXL) with six studies. Get insight on CRO appointments in the full report.

Among large and mega-cap sponsors, Eli Lilly (NYSE: LLY), GlaxoSmithKline (LON: GSK) and Gilead (NASDAQ: GILD) - with 26 each - initiated the most trials in the third quarter. The report identified Alkermes (NASDAQ: ALK), with three studies initiated in the third quarter, and Bellicum Pharmaceuticals (NASDAQ: BLCM), with four studies initiated, as the most active among mid-cap and small-cap sponsors, respectively.

Across all regions, cancer-relatd trials accounted for the largest number started or scheduled to start in the 3rd quarter, with 827 trials - a significant jump over the 671 trials in the same quarter in 2015. Breast cancer was the most widely studied indication.



Central nervous system (CNS) disorders remained the second most commonly studied therapeutic area, with 364 clinical trials - an increase of 16 trials over the same period in 2015. However, clinical trials focused on depression, stress and anxiety took over the top position from studies that were focused on alcohol and drug dependence, which held the top spot in the same quarter in 2015.

The report also identified infectious diseases as the most commonly studied therapeutic area in pediatric studies, accounting for 30 of the 171 pediatric clinical trials initiated in the third quarter. CNS disorders were second, with 24 pediatric trials.


California demonstrated the highest clinical trial activity in the U.S., followed by Texas and Florida. However, all three states had a drop in the number of studies compared to the third quarter of 2015. Phase II trials represented the largest share of clinical trials initiated in North American during the quarter, at 33 percent compared to 30 percent in the same quarter in 2015, according to BioPharm Insight data.

In Europe, Germany was the most active country, followed by France and the United Kingdom, even though each country also demonstrated a drop in the number of initiated or scheduled-to-initiate clinical trials compared to the same time period in 2015.

Japan overtook China as the most active country outside of North America and Europe, with a total of 296 clinical trials started or scheduled to start in the third quarter. China was second with 247 clinical trials, followed by Australia (172) and South Korea (108).

Learn more about the CRO industry with the full report: http://www.biopharminsight.com/cro-activity-and-intelligence-report-3q16

Tweet this: .@BioPharmInsight #ClinicalTrial competitive intel report IDs most active #CROs, sponsors, indications: http://bit.ly/2eCY2DP

About BioPharm Insight

BioPharm Insight is the most comprehensive life science market intelligence and analytics solution, featuring a team of investigative journalists writing exclusive news and thousands of healthcare data points, aggregated into one centralized source. In addition to the proprietary articles, BioPharm Insight is currently tracking 500,000 management and R&D contacts, 7,500 biopharma companies with full pipeline data, 120,000 investigational and approved drug profiles, 28,000 M&A and licensing deals, 10,000 extended sales forecasts and epidemiology profiles for hundreds of indications. Meet with BioPharm Insight in person at BIO-Europe in November and the 35th Annual J.P. Morgan Conference in January 2017. Learn more at www.biopharminsight.com and follow us: @BioPharmInsight.


[ Back To TMCnet.com's Homepage ]